hong-kong-gdp-requirements-2026.png

Good Distribution Practice (GDP) HK Audit

Anticipating the HK Drug Office's Q3 2026 GDP guidelines, DQS delivers international-standard, third-party GDP audits for pharma wholesalers, manufacturers, and 3PLs, backed by our German HQ's proven PIC/S and EU GDP expertise.


DQS Expands to Offer Audits and Certifications Aligned with EU GDP Standards

DQS Hong Kong has successfully aligned its technical qualifications with our German Headquarters (DQS HQ). Effective immediately, we officially offer third-party audit and certification services across Hong Kong and the Asia-Pacific region, fully compliant with EU GDP Guidelines (2013/C 343/01) and PIC/S standards.

DQS is committed to providing licensed manufacturers (ML), wholesale dealers (WDL), and third-party logistics providers (3PL) with authoritative compliance assessments and certification credentials—enabling businesses to establish internationally compliant quality management systems and seamlessly integrate into the global pharmaceutical supply chain.

Why Focus on GDP Compliance Now?

The Hong Kong Drug Office plans to officially issue the Guidelines on Good Distribution Practice (GDP) for Pharmaceutical Products in Q3 2026, based on international standards PIC/S PE 011-1 (finished products) and PI 047-1 (active substances):

  • New Applicants: GDP compliance will be incorporated as a licensing condition for Wholesaler Licences (WDL) and Manufacturer Licences (ML) starting Q3 2026.
  • Existing Licence Holders: Full compliance must be achieved by Q3 2028.
  • Key Takeaway: The Hong Kong government will enforce GDP compliance solely as a licensing condition and will not issue separate GDP certificates. Companies seeking to demonstrate GDP compliance to European clients or international supply chain partners must rely on globally recognized third-party audits and assessments.

(Internal Link: Hong Kong GDP Requirements 2026: Who Must Comply, When It Starts, and Do You Need a Certificate?)

What we deliver

  • Gap Analysis against the GDP Guide (HK) Ver 2026

Clause-by-clause assessment against Part I (pharmaceutical products) and, where applicable, Part II (active substances). You receive a prioritised findings register separating three categories that matter:

  1. Compliant
  2. Practised but undocumented — the largest and most under-estimated category. "We've always done it this way" with no record counts as not done.
  3. Absent
  • Independent Readiness Audit

Performed once your QMS is implemented, by auditors experienced in PIC/S and international standards — verifying that core requirements are genuinely covered, not merely written down.

  • GDP Guide (HK) Understanding Course

The course is for RPs, QA, warehouse, and logistics personnel. Covers the GDP Guide itself and the SOPs that operationalise it. It can be delivered in Cantonese, English, or Mandarin as agreed in advance.

  • International GDP Certification

For organisations that also need a management system certification for cross-border supply chain access — see our [GDP Certification]. It covers Hong Kong GDP standards as well as international frameworks including EU, WHO, and USP.

Who this is for

  • Licensed wholesale dealers (WDL holders)

Directly regulated. This is a mandatory requirement for maintaining your licence.

  • Licensed manufacturers (ML holders)

You already comply with the Board's GMP Guide — but GDP brings the distribution stage out as an explicit, separate set of requirements. GMP does not cover whether your carrier maintained temperature.

  • Logistics, warehousing and transport providers

You may hold no licence at all — and you are still exposed. WDL holders must control outsourced activities and gather and consider the relevant background information of their contract acceptors. Your customers are going to audit you. A 3PL without demonstrable GDP capability gets designed out of the pharmaceutical supply chain.

  • Medical gas businesses

Medical gases are regulated as pharmaceutical products from 14 June 2026. You are absorbing two regulatory shifts at once.

  • One-person and small operators

The Guide is explicit: a WDL holder which is a one-person company should also develop a quality system. Proportionate in scale — but it must exist.

Why "we have until 2028" is the wrong conclusion

  • Gap analysis: The implementation process usually begins with a gap analysis, taking about one to two months to identify discrepancies between current practices and regulatory requirements.
  • SOPs and system documentation: This is a longer stage, typically lasting four to eight months, during which procedures are written and systems formally documented.
  • Training and personnel qualification: Once the framework is established, focus shifts to training and personnel qualification, generally requiring two to three months to ensure staff are competent and certified.
  • Warehouse temperature mapping: This must cover both summer and winter extremes, spanning twelve months to capture seasonal variations.
  • Transport route qualification: Usually takes three to six months to validate logistics pathways.
  • First self‑inspection and CAPA closure: A two to three‑month process to identify and correct deficiencies.
  • External verification and remediation: Finally, the process concludes with external verification and remediation, requiring an additional two to four months to complete independent audits and address findings.

Temperature mapping is the binding constraint. Demonstrating your warehouse holds temperature at the hottest and coldest points of the year requires a full annual cycle. It cannot be compressed. It cannot be bought faster.

Start in late 2027 and you will not have the seasonal data.

And if you are applying for a new licence, opening a new warehouse, or standing up a new entity — your deadline is 2026, not 2028.

Why DQS

  • Auditors experienced in international GDP standards — the specific expertise aligned with the GDP Guide requirements.
  • Local presence in Hong Kong, with global pharmaceutical supply chain reach
  • We tell you what the documents actually say — including the parts that mean you need less from us than you expected
Business28.png

Certification Process

Understand the company's current status and goals to provide a customized solution.

Conduct on-site evaluations of warehousing, transportation, and supply chain partner processes and execution.

Submit audit results to an independent certification board for evaluation.

Issue the official compliance certificate or evaluation report upon approval.

Perform annual reviews to ensure ongoing regulatory compliance.

Business2.png

What you can expect from us

  • Technical Synergy & Alignment: PIC/S GDP guidelines are benchmarked against EU standards; DQS German headquarters brings mature EU GDP audit expertise.
  • Global Recognition: Third-party GDP certifications issued by DQS carry high commercial value and recognition across global supply chains and export markets.
  • End-to-End Support: Comprehensive solutions covering GDP compliance requirements across the entire supply chain.
  • Localized Expertise in Greater China: Our Hong Kong local team combines international standards from German headquarters to provide practical, tailored audit recommendations.

Frequently asked questions

  • Will DQS certification satisfy the Pharmacy and Poisons Board?

No — and no third party's will. Compliance is confirmed by the Board through licensing conditions and inspection. Our role is to find the gaps before the inspector does.

  • Can your audit replace our self-inspection?

No. The Guide states plainly that replacing self-inspections with external audits or regulatory inspections is not acceptable. Our findings can inform how you scope your self-inspections.

  • Is the GDP Guide actually law?

Not legislation itself. Its force comes from the Pharmacy and Poisons Ordinance (Cap. 138) and Regulations (Cap. 138A), which require a licence — and the Board attaches GDP compliance as a licensing condition. Technically not law; operationally mandatory.

  • Which standard does Hong Kong use?

PIC/S PE 011-1 (medicinal products → Part I) and PIC/S PI 047-1 (active substances → Part II).

  • We're already EU GDP certified — are we covered in Hong Kong?

Substantially convergent, but not identical documents. Your existing system is a strong head start; it still needs mapping against the HK Guide, and HK's enforcement mechanism differs. We can scope a delta assessment.

  • We only deal in chemical reagents / hair dyes / industrial chemicals.

Trade dealing solely in non-medicinal poisons is out of scope. The word "solely" is doing all the work — any pharmaceutical product in your range removes the exemption.

  • Are the documents final?

No. The consultation closed 31 May 2026; the Board will finalise after considering stakeholder feedback, with promulgation tentatively Q3 2026. Wording may change. We track this and adjust scope accordingly.

 

→ [Read the full breakdown of the Hong Kong GDP requirements]

The inspector will find what you didn't look for

Give us a scope, and we'll tell you honestly how far you are — including if the answer is "closer than you think."

Request a quote